NAD+

A coenzyme central to cellular metabolism, sold in injectable form through peptide channels with limited bioavailability evidence.

NAD+ is classified as a coenzyme. Its current development status is: preclinical / limited clinical. Most of the evidence is preclinical. Human data is early, small, or absent for the uses commonly discussed.

The Peptide Institute tracks NAD+ because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.